SignalHF vs ElucidVivo A.3
AI Verdict
Choose SignalHF if…
Choose SignalHF if your primary objective is to proactively reduce heart failure hospitalizations in patients with cardiac implantable electronic devices (CIEDs). This FDA-cleared AI algorithm excels at predicting heart failure events within 30 days by analyzing comprehensive CIED data, enabling care teams to implement early interventions and tailor personalized care plans.
View SignalHF →Choose ElucidVivo A.3 if…
Choose ElucidVivo A.3 if you need an advanced, quantitative analysis of arterial plaque composition and stability from CT angiography to guide atherosclerosis management. This AI-powered system provides detailed visualization and objective measurements of plaque characteristics, such as lipid-rich necrotic core, to optimize patient stratification and treatment decisions for cardiovascular disease.
View ElucidVivo A.3 →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | SignalHF | ElucidVivo A.3 |
|---|---|---|
| Pricing | Contact for pricing | Unknown |
| Deployment | SaaS | Cloud and on-premise secure deployment. |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | SignalHF | ElucidVivo A.3 |
|---|---|---|
| Tool Name | SignalHF | ElucidVivo A.3 |
| Company | Implicity | Elucid Bioimaging |
| Description | SignalHF by Implicity is an FDA-cleared AI algorithm that predicts heart failure hospitalizations within 30 days by analyzing data from various cardiac implantable electronic devices, enabling early intervention and personalized care. | ElucidVivo A.3 by Elucid Bioimaging is an FDA-cleared AI-powered medical image analysis system that provides quantitative analysis of arterial plaque composition and stability from CT angiography. It assists physicians in atherosclerosis patient stratification and optimizes treatment decisions by offering detailed visualization and measurement of plaque characteristics validated against histology. |
| Primary Function | Predicts heart failure hospitalizations within 30 days by analyzing data from various cardiac implantable electronic devices. | Provides quantitative analysis of arterial plaque composition and stability from CT angiography to assist in atherosclerosis patient stratification and treatment decisions. |
| Key Data Analyzed | Physiological data, demographics, lead measurements, episodes, and therapies from CIEDs. | CT angiography images for arterial plaque composition (Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications). |
| Specialties | Cardiology | Cardiology, Radiology, Vascular Surgery |
Videos
Demos, reviews, and walkthroughs featuring SignalHF and ElucidVivo A.3.